Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

and the immune response of resident corneal cells. Corneal disease in vernal keratoconjunctivitis and atopic keratoconjunctivitis currently requires aggressive treatment with topical steroids.

launched Vyznova neltependocel in Japan for the treatment of bullous keratopathy, a corneal endothelial disease. This cell therapy is paving new ground by offering a less invasive alternative to ...

It can be hard to tell a scratched cornea (corneal abrasion) from pink eye (also known as conjunctivitis). They can have similar symptoms, including eye redness, tearing, and sensitivity to light.

Deerfield Management accused Alcon of obstructing Aurion’s IPO plans so it could acquire the startup “at a discount.” ...